Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Seite 2

Location: Poster Section 28; Poster Board Number 8
Presented by Hans-Georg Lerchen, Ph.D., Vincerx Pharma

Title: Addressing drug metabolism and pharmacokinetics (DMPK) challenges of small molecule-drug conjugates (SMDCs)
Abstract Number: 3197
Session Category: Experimental and Molecular Therapeutics
Session Title: Cancer Immunotherapy and Drug Delivery
Session Date and Time: Monday, April 8, 2024, 1:30 PM – 5:00 PM PT
Location: Poster Section 23; Poster Board Number 14
Presented by Anne-Sophie Rebstock, Ph.D., Vincerx Pharma

A copy of the presentation materials can be accessed on the Investors section of the Company’s website at https://investors.vincerx.com/news-events/presentations once each presentation has concluded.

About VIP236

VIP236, the first-in-class small molecule drug conjugate (SMDC) from our VersAptx Platform, consists of an α_vβ₃ integrin binder, a neutrophil elastase linker cleaved in the tumor microenvironment, and a camptothecin payload optimized for high permeability and low efflux. VIP236 was designed to deliver its payload to advanced/metastatic tumors that express α_vβ₃. Preclinical data show enhanced efficacy, independent of HER2 status, in patient-derived and cell line-derived gastric cancer models compared with ENHERTU, an approved ADC. VIP236 is being evaluated in a Phase 1 dose-escalation trial treating patients with advanced or metastatic solid tumors (NTC05371054). As VIP236 is a first-in-class drug, the Phase 1 trial is evaluating various dosing schedules. To date, 20 patients with advanced or metastatic disease that has relapsed or is refractory to standard of care have received VIP236.

About VIP943

VIP943, the first ADC from our VersAptx platform, consists of an anti-CD123 antibody, a unique linker cleaved intracellularly by legumain, and a novel kinesin spindle protein inhibitor (KSPi) payload enhanced with our CellTrapper technology. Our proprietary effector chemistry (linker + payload) was designed to reduce non-specific release of the payload and ensure payload accumulation in cancer cells versus healthy cells. The increased therapeutic index has the potential to address challenges associated with many ADCs by improving efficacy and reducing severe toxicities. VIP943 is in a Phase 1 dose-escalation trial evaluating patients with relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia who have exhausted standard therapeutic options (NCT06034275). Preliminary pharmacokinetic data from the first cohort shows low levels of unconjugated payload (VIP716) in circulation, as predicted from preclinical experiments. Reduced nonspecific release of payload is one of many features engineered into VIP943 to increase the therapeutic index compared with existing technologies. We expect to expand into additional CD123-positive indications, including TP53 mutated AML, both as monotherapy and in combination, as safety and efficacy data are generated. Preliminary Phase 1 data are expected in mid-2024.